文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

局部晚期宫颈癌同步放化疗后BMS-VMAT的动态免疫变化

Dynamic immune changes after bone marrow sparing VMAT in women with locally advanced cervical cancer treated with chemoradiotherapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-01-16

本研究评估局部晚期宫颈癌女性在接受骨髓保护(BMS)容积旋转调形放疗(VMAT)同步放化疗后的血液免疫组成与功能变化,并与采用非BMS放疗的历史队列探索性比较。结果显示BMS VMAT虽使盆腔平均骨剂量降低8.1 Gy,但未阻止治疗诱导的白细胞减少和淋巴细胞减少;CD4+辅助T细胞和B细胞主要减少,CD8+ T细胞和自然杀伤细胞频率未受影响,T细胞对常见病原体的反应性下降但增殖能力保留,调节性T细胞增多,免疫激活潜力仍完整。

要点

  • BMS VMAT使盆腔平均骨剂量降低8.1 Gy,但未阻止同步放化疗所致白细胞减少和淋巴细胞减少。
  • 同步放化疗主要减少CD4+辅助T细胞和B细胞,CD8+ T细胞与NK细胞频率未受明显影响。
  • T细胞对常见病原体反应性下降,调节性T细胞增多,但髓系细胞抗原提呈与激活T细胞能力保留。

核心结论

  • BMS VMAT同步放化疗仍出现免疫抑制,需优化骨髓保护并探索其他技术。

主要发现

  • BMS VMAT使盆腔平均骨剂量降低8.1 Gy,但未阻止治疗诱导的白细胞减少和淋巴细胞减少。
  • 同步放化疗主要减少CD4+辅助T细胞和B细胞,CD8+ T细胞和自然杀伤细胞频率未受影响。
  • T细胞对常见病原体反应性下降,但T细胞增殖能力持续,调节性T细胞数量增加。
  • 免疫细胞激活潜力保持完整,树突状细胞小幅增加,髓源性抑制细胞减少,髓系细胞抗原提呈和激活T细胞能力保留。

临床怎么用

  • BMS VMAT可降低盆腔骨剂量,但临床仍需监测并管理同步放化疗所致白细胞减少和淋巴细胞减少。
  • 免疫功能评估可关注CD4+ T细胞、B细胞及调节性T细胞变化,CD8+ T细胞和NK细胞频率未必反映免疫抑制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chemoradiotherapy is immunosuppressive in women with locally advanced cervical cancer (LACC). Both advanced external-beam radiation therapy (EBRT) and bone marrow sparing (BMS) radiotherapy techniques might lower bone marrow dose and therefore reduce the impact on the immune system. In this study, immune composition and function changes in the blood of women with LACC were evaluated for BMS volumetric-modulated arc therapy (VMAT) and exploratively compared with a historical cohort of women with LACC who underwent non-BMS radiotherapy (RT) with older EBRT techniques. METHODS: Women were treated with chemoradiotherapy followed by brachytherapy according to EMBRACE-II protocol (BMS VMAT) or with 46-52.5 Gy in 23-30 fractions (non-BMS RT). Blood samples for immunomonitoring were collected at set timepoints. Statistical analyses were performed using linear mixed-effects models. RESULTS: Eighteen and eleven women received BMS VMAT and non-BMS RT, respectively. Although BMS VMAT reduced mean pelvic bone dose by 8.1 Gy, it did not prevent treatment-induced leukopenia and lymphopenia. Chemoradiotherapy mainly reduced CD4+ T helper cells and B cells, leaving CD8+ T-cell and natural killer-cell frequencies untouched. T-cell reactivity to common pathogens was decreased, despite sustained T-cell proliferative capacity, and coincided with increased numbers of regulatory T cells. The potential to activate immune cells remained intact, with small increases in dendritic cells, decreases in myeloid-derived suppressor cells, and preserved capacity of myeloid cells to present antigen and activate T cells. CONCLUSION: Our study provided insight in the dynamic immune changes following chemoradiotherapy in LACC. As immunosuppression occurred with BMS VMAT, optimizing BMS and exploring other techniques is warranted.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Corbeau A, Welters MJP, Boekestijn S, et al. Dynamic immune changes after bone marrow sparing VMAT in women with locally advanced cervical cancer treated with chemoradiotherapy. Clin Transl Radiat Oncol. 2026. PMID: 41675144. doi:10.1016/j.ctro.2026.101107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。